Tallahassee, FL-----Florida A&M University (FAMU) College of Pharmacy and Pharmaceutical Sciences (COPPS) Associate Professor, Nazarius S. Lamango, PhD., recently received a U.S. Patent (U.S. 7,897,604) that will help diagnosis and treat Triple Negative Breast Cancer (TNBC). According to the National Cancer Institute (NCI), Triple Negative Breast Cancer (TNBC). According to the National Cancer Institute (NCI), Triple Negative Breast Cancer disproportionately affects African American and Hispanic Women.

Moreover, approximately one in eight women will develop invasive breast cancer in her lifetime. However, breast cancer incidence and death rates have been declining during the past decade, thanks to focused research, medical advancements, and better awareness among women. Early detection and knowing the signs of breast cancer is key in the fight against breast cancer.

"Dr. Lamango's discovery is very important because it could potentially increase survival rates by providing better treatment options for women with TNBC," said Tanaga Boozer, J.D., Acting Director for the Office of Technology Transfer, Licensing and Commercialization (OTTLIC).

Dr. Lamango said, “We are very excited about this research on this particular enzyme because of the novel therapeutic potential. The abnormally high levels of the enzyme we have seen in samples from some patients coupled with the fact that we are devising ways to bring down such elevated activities to normal physiological levels and kill cancer cells in the process offers hope not only for diagnostic approaches but for treatments as well.”